XOMA Royalty (XOMA) Projected to Post Earnings on Tuesday

Key Points

• XOMA Royalty is set to report Q1 2026 results before the open on Tuesday, May 12, with analysts forecasting EPS of $0.1285 and revenue of $13.873 million; a conference call is scheduled for May 15 at 9:30 AM ET.
• The company recently beat estimates (reported $0.12 EPS vs. consensus −$0.04 and $13.76M revenue) and analysts now expect about $1 EPS for both the current and next fiscal year.
• Shares traded at $41.21 (+0.4%), giving a market cap of roughly $491 million and a P/E of ~28.2; institutional investors own ~95.9% of the stock and the Wall Street consensus rating is "Hold" with a $53.75 target.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) is expected to post its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of $0.1285 per share and revenue of $13.8730 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings data on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.16. XOMA Royalty had a return on equity of 10.32% and a net margin of 45.75%.The company had revenue of $13.76 million for the quarter, compared to the consensus estimate of $11.13 million. On average, analysts expect XOMA Royalty to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

XOMA Royalty Stock Up 0.4%

XOMA stock traded up $0.17 during trading on Tuesday, reaching $41.21. 58,603 shares of the company traded hands, compared to its average volume of 373,935. XOMA Royalty has a 12 month low of $22.29 and a 12 month high of $42.81. The business has a 50 day simple moving average of $32.10 and a 200 day simple moving average of $30.16. The company has a market capitalization of $491.22 million, a price-to-earnings ratio of 28.23 and a beta of 0.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 3.37 and a current ratio of 3.37.

Institutional Investors Weigh In On XOMA Royalty

Institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in shares of XOMA Royalty by 3,436.4% during the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 756 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of XOMA Royalty by 203.1% during the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 1,523 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of XOMA Royalty by 266.6% during the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company's stock worth $124,000 after purchasing an additional 2,346 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 543 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of XOMA Royalty during the second quarter worth about $116,000. Institutional investors and hedge funds own 95.92% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on XOMA shares. HC Wainwright downgraded XOMA Royalty from a "buy" rating to a "neutral" rating and set a $39.00 price objective on the stock. in a research report on Thursday, April 30th. TD Cowen raised XOMA Royalty to a "hold" rating in a research report on Friday, February 13th. Leerink Partners reaffirmed an "outperform" rating on shares of XOMA Royalty in a research report on Tuesday, February 24th. Lucid Cap Mkts downgraded XOMA Royalty from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 27th. Finally, Zacks Research raised XOMA Royalty from a "strong sell" rating to a "hold" rating in a report on Wednesday, April 8th. Two research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $53.75.

XOMA Royalty Company Profile

XOMA Royalty NASDAQ: XOMA is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company's business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company's investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.